Business Context and Reporting Period
This Form 8-K is filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc. as indicated in metadata) for the reporting date of March 22, 2015. The filing addresses a significant regulatory milestone regarding the company's product ZALVISOTM, a treatment for moderate-to-severe acute pain in adult patients within medically-supervised environments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements.
Material Changes and Regulatory Status
- EMA Review Progress: On March 22, 2015, Grunenthal GmbH confirmed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) received responses to the Day 120 List of Questions regarding the Marketing Authorization Application for ZALVISOTM.
- Review Initiation: The EMA has initiated the review of these responses.
- Timeline: AcelRx and Grunenthal expect to receive the EMA Day 180 List of Outstanding Issues during the second quarter of 2015.
- Process Duration: The CHMP evaluation takes up to 210 active days plus potential "clock stops," after which an opinion on marketing authorization will be adopted and transmitted to the European Commission.
Guidance, Outlook, and Agreements
AcelRx Pharmaceuticals, Inc. and Grunenthal entered into license and supply agreements for ZALVISOTM in the EU, Australia, and certain other countries in December 2013. The ultimate authority for granting marketing authorizations in the European Union rests with the European Commission following the CHMP opinion.
Investor Verification Checklist
- Verify the exact status of the Day 180 List of Outstanding Issues expected in Q2 2015.
- Confirm the terms of the December 2013 license and supply agreements between AcelRx and Grunenthal.
- Monitor the European Commission's final decision following the CHMP opinion.
- Check for any "clock stops" that may extend the 210-day evaluation period.